Home » Report: Access to Oncology Drugs Runs Narrow Despite Surge in New Therapies
Report: Access to Oncology Drugs Runs Narrow Despite Surge in New Therapies
June 8, 2016
Despite a surge in new oncology therapies in the past five years, a new report says that access to many of these drugs is limited to only a handful of countries.
A study by the IMS Institute for Healthcare Informatics shows that of the 49 new oncology drugs launched between 2010 and 2014, fewer than half were available in all but six countries: the U.S., Germany, the UK, Italy, France and Canada.
Even in these countries, access to these new therapies can still be limited because public insurance programs may not reimburse for their use. According to the report, only three countries — the U.S., France and Scotland — provide reimbursement on more than half of new cancer drugs approved between 2014 and 2015.
Upcoming Events
-
21Oct